TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Latest Form 4:Sale$355KbyWeiss Amir (Chief Accounting Officer) · filed Aug 25, 2026
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) has 64 SEC Form 4 filings (113 transaction rows) in the rolling window, disclosed by 15 distinct insiders. Most recent filing: Aug 25, 2026.
Inside the rolling window, 15 insiders at TEVA PHARMACEUTICAL INDUSTRIES LTD reported 1 open-market purchase totaling $21K and 44 open-market sales totaling $98.7M. The most active filer is President and CEO Francis Richard D with 5 filings. Insiders have net sold $63.2M over the trailing 6 months. The most recent open-market filing is a sale of 9,445 shares by Chief Accounting Officer Weiss Amir, dated Aug 21, 2026, worth $355K.
- Industry:Drug Manufacturers - Specialty & Generic
- CEO:Richard D. Francis
- Employees:32,008
- HQ:Tel Aviv, TA, IL
- IPO:1982-02-16
Insider Buying
$21K
reported purchases (SEC code P)
Insider Selling
$98.7M
reported sales (SEC code S)
Unique Insiders
15
in the rolling window
Market Cap
$42.4B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Weiss AmirFirst in 4 months | Chief Accounting Officer | Sale | 9,445 | $355K | Aug 25 | SEC ↗ |
Satchi-Fainaro RonitFirst filing | Director | Sale | 415 | $15K | Aug 25 | SEC ↗ |
Lippman EvanFirst in 3 months | EVP, Business Development | Sale | 18,600 | $680K | Aug 19 | SEC ↗ |
Zaks Tal ZviFirst filing | Director | Sale | 17 | $593 | Aug 10 | SEC ↗ |
Hughes Eric AFirst in 5 months | See "Remarks" | Sale | 25,578 | $892K | Aug 5 | SEC ↗ |
Jover PlacidFirst in 5 months | See "Remarks" | Sale | 12,827 | $447K | Aug 5 | SEC ↗ |
| EVP, Global Operations | Sale | 9,989 | $322K | Jun 22 | SEC ↗ | |
| EVP, Chief Financial Officer | Sale | 106,563 | $3.6M | Jun 16 | SEC ↗ | |
Francis Richard DFirst in 3 months | President and CEO | Sale | 6,153 | $211K | Jun 8 | SEC ↗ |
| EVP, Global Operations | Sale | 16,195 | $532K | Jun 4 | SEC ↗ | |
Lippman EvanFirst filing | EVP, Business Development | Sale | 41,658 | $1.5M | May 18 | SEC ↗ |
| EVP, Chief Financial Officer | Sale | 153,251 | $5.5M | May 18 | SEC ↗ | |
| EVP, Europe Commercial | Sale | 30,000 | $1.1M | May 7 | SEC ↗ | |
Weiss AmirFirst in 5 months | Chief Accounting Officer | Sale | 10,679 | $384K | May 7 | SEC ↗ |
| See "Remarks" | Sale | 144,180 | $5.0M | May 4 | SEC ↗ | |
| EVP, U.S. Commercial | Sale | 21,258 | $751K | May 4 | SEC ↗ | |
Sabag MarkFirst in 3 months | See "Remarks" | Sale | 62,102 | $1.9M | Mar 19 | SEC ↗ |
| EVP, Europe Commercial | Sale | 17,295 | $548K | Mar 9 | SEC ↗ | |
Shields MatthewFirst filing | EVP, Global Operations | Sale | 17,295 | $548K | Mar 9 | SEC ↗ |
| See "Remarks" | Sale | 9,533 | $302K | Mar 9 | SEC ↗ | |
Jover PlacidFirst filing | See "Remarks" | Sale | 14,150 | $448K | Mar 9 | SEC ↗ |
| President and CEO | Sale | 20,025 | $634K | Mar 9 | SEC ↗ | |
| Interim Chief Legal Officer | Sale | 1,127 | $36K | Mar 9 | SEC ↗ | |
| EVP, U.S. Commercial | Sale | 7,924 | $251K | Mar 9 | SEC ↗ | |
| Interim Chief Legal Officer | Sale | 2,675 | $87K | Mar 6 | SEC ↗ | |
| EVP, Europe Commercial | Sale | 91,345 | $3.0M | Mar 6 | SEC ↗ | |
| President and CEO | Sale | 23,393 | $759K | Mar 6 | SEC ↗ | |
Fox ChristineFirst in 3 months | EVP, U.S. Commercial | Sale | 9,098 | $295K | Mar 6 | SEC ↗ |
| See "Remarks" | Sale | 11,277 | $366K | Mar 6 | SEC ↗ | |
| EVP, Europe Commercial | Sale | 128,985 | $4.2M | Mar 5 | SEC ↗ | |
| President and CEO | Sale | 442,935 | $14.3M | Mar 5 | SEC ↗ | |
Hughes Eric AFirst filing | See "Remarks" | Sale | 80,762 | $2.6M | Mar 5 | SEC ↗ |
Savage BrianFirst filing | Interim Chief Legal Officer | Sale | 1,274 | $41K | Mar 5 | SEC ↗ |
Kalif Eliyahu SharonFirst filing | EVP, Chief Financial Officer | Sale | 345,810 | $11.6M | Mar 2 | SEC ↗ |
Francis Richard DFirst filing | President and CEO | Sale | 447,778 | $15.3M | Feb 18 | SEC ↗ |
| Director | Sale | 77,400 | $2.3M | Dec 18 | SEC ↗ | |
| Chief Accounting Officer | Sale | 12,300 | $372K | Dec 18 | SEC ↗ | |
Daniell RichardFirst filing | Exec. VP, European Commercial | Sale | 115,468 | $3.3M | Dec 11 | SEC ↗ |
Sabag MarkFirst filing | See "Remarks" | Sale | 216,892 | $6.2M | Dec 11 | SEC ↗ |
| Director | Sale | 50,000 | $1.3M | Dec 1 | SEC ↗ | |
| EVP, Head of U.S. Commercial | Sale | 28,229 | $700K | Nov 24 | SEC ↗ | |
Fox ChristineFirst filing | EVP, Head of U.S. Commercial | Sale | 30,000 | $753K | Nov 18 | SEC ↗ |
MIGNONE ROBERTOFirst filing | Director | Sale | 200,000 | $4.8M | Nov 10 | SEC ↗ |
Weiss AmirFirst filing | Chief Accounting Officer | Sale | 12,300 | $301K | Nov 10 | SEC ↗ |
McAvoy David R.First filing | EVP, Chief Legal Officer | Purchase | 1,113 | $21K | Sep 9 | SEC ↗ |
Frequently asked questions
How many SEC Form 4 insider filings does TEVA have?
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) has 64 SEC Form 4 filings (113 transaction rows) in the rolling 365-day window, disclosed by 15 distinct insiders. Most recent filing: Aug 25, 2026.
When was the most recent SEC Form 4 filing for TEVA?
The most recent Form 4 filing for TEVA on Tracefour is dated Aug 25, 2026.
Who is the most active insider at TEVA?
The most active SEC Form 4 filer at TEVA in the rolling window is President and CEO Francis Richard D, with 5 filings.
What is the net insider flow at TEVA over the last 6 months?
Over the trailing 180 days, insiders at TEVA have net sold $63.2M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at TEVA in the current window?
Inside the rolling window, insiders at TEVA bought $21K and sold $98.7M based on SEC Form 4 filings.
Can I get alerts for TEVA insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
TEVA PHARMACEUTICAL INDUSTRIES LTD is in the Healthcare sector.